PMID- 19596662
OWN - NLM
STAT- MEDLINE
DCOM- 20091112
LR  - 20220408
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 39
IP  - 11
DP  - 2009 Nov
TI  - Elevating blood pressure as a strategy to increase tumor-targeted delivery of 
      macromolecular drug SMANCS: cases of advanced solid tumors.
PG  - 756-66
LID - 10.1093/jjco/hyp074 [doi]
AB  - The purpose of this study is to evaluate the improved method of arterial infusion 
      therapy of SMANCS (SX) with lipiodol under the angiotensin-induced hypertensive 
      state for various difficult-to-treat solid tumors. Most patients were 
      unresectable with no other therapeutic options, recurrence after resection, or 
      patients do not respond to common treatments. The new method utilizes angiotensin 
      II (AT) to induce hypertension (e.g. approximately 15-30 mmHg above norm) for 
      15-20 min. This method was successfully applied to metastatic liver cancer, 
      cholangiocarcinoma, massive renal cell carcinoma, pancreatic and other abdominal 
      solid cancers. This AT-induced hypertension resulted in remarkably enhanced tumor 
      delivery accompanied by improved therapeutic response, and a shorter time to 
      achieve 50% regression of tumor size with least toxicity. We demonstrated 
      clinically herein improved therapy for various advanced solid tumors with SX by 
      elevating the tumor blood flow selectively. This is the first clinical proof that 
      modulations of vascular pathophysiology can uniquely accomplish enhanced tumor 
      selective delivery of polymeric drugs and thus yielded better clinical outcome.
FAU - Nagamitsu, Akinori
AU  - Nagamitsu A
AD  - Kumamoto Hakuaikai Hospital, Kumamoto, Japan.
FAU - Greish, Khaled
AU  - Greish K
FAU - Maeda, Hiroshi
AU  - Maeda H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090711
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Maleic Anhydrides)
RN  - 0 (Polystyrenes)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (poly(maleic acid-styrene)neocarzinostatin)
RN  - 11128-99-7 (Angiotensin II)
RN  - 9014-02-2 (Zinostatin)
SB  - IM
MH  - Adenocarcinoma/drug therapy
MH  - Adult
MH  - Aged
MH  - Angiotensin II/*administration & dosage
MH  - Antineoplastic Agents/*administration & dosage
MH  - Blood Pressure/*drug effects
MH  - Carcinoma, Renal Cell/drug therapy
MH  - Cholangiocarcinoma/drug therapy
MH  - Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Hypertension/*chemically induced
MH  - Infusions, Intravenous
MH  - Japan
MH  - Kidney Neoplasms/drug therapy
MH  - Liver Neoplasms/drug therapy
MH  - Male
MH  - Maleic Anhydrides/*administration & dosage
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms/*blood supply/*drug therapy/pathology
MH  - Ovarian Neoplasms/drug therapy
MH  - Pancreatic Neoplasms/drug therapy
MH  - Polystyrenes/*administration & dosage
MH  - Vasoconstrictor Agents/*administration & dosage
MH  - Zinostatin/administration & dosage/*analogs & derivatives
EDAT- 2009/07/15 09:00
MHDA- 2009/11/13 06:00
CRDT- 2009/07/15 09:00
PHST- 2009/07/15 09:00 [entrez]
PHST- 2009/07/15 09:00 [pubmed]
PHST- 2009/11/13 06:00 [medline]
AID - hyp074 [pii]
AID - 10.1093/jjco/hyp074 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2009 Nov;39(11):756-66. doi: 10.1093/jjco/hyp074. Epub 2009 Jul 
      11.